Biologics contract development market seen reaching $14.46 billion by 2030

The biologics contract development market is projected to grow from $8.55 billion in 2025 to $14.46 billion by 2030, according to The Business Research Company. Rising chronic disease burden, outsourcing demand and expansion in biologics pipelines are driving the outlook, with Asia-Pacific expected to be the fastest-growing region.

Why it matters: - Biologics contract development is becoming a bigger part of drug development as pharmaceutical companies outsource more work to specialized providers. - The market’s projected growth points to rising demand for faster biologics development, scale-up capacity and manufacturing flexibility. - Chronic diseases are increasing the need for new biologic therapies, which supports more contract development activity.

What happened: - The Business Research Company said the biologics contract development market will grow from $8.55 billion in 2025 to $9.53 billion in 2026. - The company projected the market will reach $14.46 billion by 2030. - The forecast implies an 11.4% CAGR from 2025 to 2026 and an 11.0% CAGR through 2030. - The report covers global market size, trends and forecasts for 2026-2035. - Download a free sample of the biologics contract development market report. - View the full biologics contract development market report.

The details: - Biologics contract development means specialized companies provide development and manufacturing services for biologic drugs under contract to pharmaceutical firms. - The outsourcing model allows pharmaceutical companies to focus on marketing, research and development, and brand building. - Growth over the recent period has been driven by more complex biologics pipelines, higher in-house manufacturing costs, growth in monoclonal antibody development, more early-stage biologics research and greater reliance on contract development and manufacturing organizations. - The report says future growth will be supported by rapid biologics scale-up needs, more investment in advanced mammalian cell platforms, expanding oncology biologics pipelines, demand for flexible manufacturing capacity and broader use of digital bioprocess optimization. - Key trends include more outsourcing of biologics process development, higher demand for scalable cell line development, wider use of single-use bioprocessing systems, more integrated CDMO service models and a stronger focus on speed-to-clinic development. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast reflects a broader shift in biopharma toward outsourcing specialized and capital-intensive work. - Higher demand for biologics development services suggests drugmakers want shorter timelines and more adaptable production systems. - The chronic disease backdrop gives the market a structural tailwind rather than a short-term boost. - In September 2024, the UK government’s Office for Health Improvement & Disparities reported 3,940 excess deaths from chronic lower respiratory diseases in the first half of 2023, a 30% increase versus expected levels. - The same report said excess deaths for the full year 2023 reached 5,363, up 22% overall.

What's next: - The market is expected to keep expanding as biologics pipelines grow and manufacturers look for more efficient development capacity. - Asia-Pacific’s projected growth suggests more contract development activity may shift toward the region over the next several years. - The Business Research Company said its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards and market hotspot infographics. - The company also highlighted updated graphics, tables and future trend analysis in the new report set.

The bottom line: - Biologics contract development is moving from niche support service to a larger strategic layer in drug development, with strong growth expected through 2030.